Clinical Trial Update: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) [Phase 4]

View source ↗

Summary

Phase 4 open-label study assessing pharmacokinetics, efficacy, and safety of ASCENIV IGIV in pediatric patients with primary immunodeficiency diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disease

Drugs mentioned

• ASCENIV (immune globulin intravenouS)

Snippet

Sponsor: ADMA Biologics, Inc. | Conditions: Primary Immune Deficiency | Phase 4 | Status: UNKNOWN